Ardelyx Inc
ARDX
NASDAQ
Biotechnology
$4.06
USD
+0.15 (+3.84%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $974.32M
Volume 4.0M
Revenue
$450.89M
TTM
+16.8%
YoY
Gross Margin
94%
TTM
+11.3%
YoY
Net Income
$-55.70M
TTM
+1.2%
YoY
Operating Cash Flow
$-17.32M
TTM
+67.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 97.7 | 110.3 | 125.2 | 94.5 | 120.9 |
YoY Growth | +33.4% | +12.3% | +7.8% | +27.5% | +23.8% |
Cost of Revenue | 12.4 | 4.0 | 10.8 | 4.8 | 5.8 |
Gross Profit | 85.3 | 106.3 | 114.4 | 89.7 | 115.1 |
Selling, General & Administrative | 84.0 | 83.6 | 86.4 | 102.3 | 101.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 99.7 | 101.7 | 109.3 | 122.5 | 127.5 |
Operating Income | -14.4 | 4.7 | 5.1 | -32.8 | -12.4 |
EBITDA | -13.8 | 5.6 | 6.0 | -31.9 | -11.8 |
Other Income / Expense | 1.9 | 2.4 | -6.2 | 2.1 | 2.0 |
Total Other Income / Expense | -4.7 | -5.5 | -5.5 | -4.8 | -4.2 |
Income Before Income Taxes | -19.1 | -0.9 | -0.4 | -37.6 | -16.6 |
Income Taxes | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 |
Net Income | -19.1 | -1.0 | -0.4 | -37.6 | -16.7 |
Consolidated Net Income / Loss | -19.1 | -1.0 | -0.4 | -37.6 | -16.7 |
Net Income Attributable to Common Shareholders | -19.1 | -1.0 | -0.4 | -37.6 | -16.7 |
Basic EPS | -$0.08 | $0.00 | $0.00 | -$0.15 | -$0.07 |
Diluted EPS | -$0.08 | $0.00 | $0.00 | -$0.15 | -$0.07 |
Basic Shares Outstanding | 239.9M | 241.9M | 243.7M | 245.9M | 248.1M |
Diluted Shares Outstanding | 239.9M | 241.9M | 243.7M | 245.9M | 248.1M |